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Objectives This study sought to determine the usefulness of plasma growth differentiation factor 15 (GDF-15) for risk strati-
fication in patients undergoing cardiac surgery in comparison with the additive European System of Cardiac Op-
erative Risk Evaluation (EuroSCORE), N-terminal pro–B-type natriuretic peptide (NTproBNP), and high-sensitive
troponin T (hsTNT).
Background GDF-15 is emerging as a humoral marker for risk stratification in cardiovascular disease. No data are available
if this marker may also be used for risk stratification in cardiac surgery.
Methods In total, 1,458 consecutive patients were prospectively studied. Pre-operative plasma GDF-15, NTproBNP, hsTNT,
clinical outcomes, and 30-day and 1-year mortality were recorded. GDF-15 was determined with a pre-
commercial electrochemiluminescence immunoassay.
Results Median additive EuroSCORE (addES) was 5 (interquartile range: 3 to 8); 30-day and 1-year mortality were 3.4%
and 7.6%, respectively. Median GDF-15 levels were 1.04 ng/ml (95% confidence interval [CI]: 1.0 to 1.07 ng/ml)
in 30-day survivors and 2.62 ng/ml (95% CI: 1.88 to 3.88) in 30-day nonsurvivors (p  0.0001). C-statistics
showed that the area under the curve of a combined model of GDF-15 and addES for 30-day mortality was signifi-
cantly greater (0.85 vs. 0.81; p  0.0091) than of the addES alone. For the EuroSCORE categories (0 to 2, 3 to 5, 6
to 10, 10) the presence of GDF-15 1.8 ng/ml resulted in a significant 41.4% (95% CI: 19.2 to 63.7%; p  0.001)
net reclassification improvement and an integrated discrimination improvement of 0.038 (95% CI: 0.022 to 0.0547;
p  0.0001) compared to the model including only the addES, whereas the presence of NTproBNP (cutoff 2,000
pg/ml) or hsTNT (cutoff 14 pg/ml) did not result in significant reclassification.
Conclusions The pre-operative plasma GDF-15 level is an independent predictor of post-operative mortality and morbidity in
cardiac surgery patients, can further stratify beyond established risk scores and cardiovascular markers, and
thus adds important additional information for risk stratification in these patients. (The Usefulness of Growth
Differentiation Factor 15 [GDF-15] for Risk Stratification in Cardiac Surgery; NCT01166360). (J Am Coll Cardiol
2013;61:672–81) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.059Growth differentiation factor (GDF)-15, formerly entitled
macrophage-inhibitory cytokine, is a member of the trans-
forming growth factor family (1). Low quantities of
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2012, accepted September 30, 2012.GDF-15 are expressed in most tissues, including myocar-
dium, lung, kidney, brain, liver, and the intestine. Increased
expression of this cytokine can be induced by myocardial
stretch, volume overload, and experimental cardiomyopathy
as well as oxidative stress, inflammatory cytokines, and
ischemia/reperfusion (2), suggesting that the plasma levels
of this cytokine are not only related to myocardial dysfunc-
tion but also to circulatory stress.
See page 682
Recent data revealed that the plasma concentrations of
this peptide may be used for predicting short- and long-
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February 12, 2013:672–81 GDF-15 for Risk Stratification in Cardiac Surgeryterm mortality in patients with coronary artery disease (3),
myocardial infarction (4), and chronic heart failure (5,6).
Interestingly, in some of these studies, GDF-15’s predic-
tive capacity was additive or even superior to conventional
isk markers such as N-terminal pro–B-type natriuretic
eptide (NTproBNP) (6) or high-sensitive troponin T
hsTNT) (7).
The present study was designed to determine the useful-
ess of GDF-15 for risk stratification in patients undergo-
ng cardiac surgery and if plasma levels of this cytokine add
rognostic information to conventional risk stratification
trategies such as the additive European System of Cardiac
perative Risk Evaluation (EuroSCORE) (addES) and
markers of cardiovascular dysfunction like NTproBNP or
hsTNT.
Methods
Study design. The study was designed as a prospective
observational cohort study and is part of a project analyzing the
prognostic relevance of pre-operative cerebral oxygen satura-
tion and markers of cardiopulmonary dysfunction with respect
to clinical outcomes in patients undergoing cardiac surgery (8).
The primary objective of the present analysis was to
etermine the relation between pre-operative plasma
DF-15 levels and 30-day mortality in comparison with
he additive EuroSCORE as well as to investigate if
DF-15 levels can further improve risk stratification of
atients undergoing cardiac surgery beyond that obtained by
his established risk score.
The secondary objective was to determine the usefulness
f GDF-15 for predicting 1-year mortality and major
omplications as well as to determine the additive informa-
ion of GDF-15 in comparison with NTproBNP (10) and
sTNT (7).
atients. Following approval by the local ethical commit-
ee (Ethikkommission der Universität zu Lübeck, Lübeck,
ermany) all patients scheduled for cardiac surgery at the
niversity of Lübeck from January 1, 2008, to December 1,
008, and from April 1, 2009, to December 31, 2009, were
creened for participation in this prospective, observational
rial. The exclusion criterion was age 18 years. Written
nformed consent was obtained from all elective and urgent
atients as well as emergency patients capable to commu-
icate. In case of sedated and/or intubated patients sched-
led for emergency surgery consent was obtained from the
ext of kin and reconfirmed after recovery.
It was our primary intention to analyze the association
etween pre-operative GDF-15 levels and clinical outcomes
n a “derivation” cohort of patients undergoing cardiac
urgery in 2009 and to confirm our findings in a “validation”
ohort of patients. The latter should be accomplished by
sing stored plasma samples of a cohort of patients studied
n 2008 that has been described recently (8). Unfortunately,
nd for unresolved reasons, a relevant number of plasma
pecimen were lost during transport and/or analysis. Con- gequently, plasma samples were
nly available from 499 of 796
atients in the derivation cohort
Fig. 1). Because the low event
ate (30-day mortality: 3.4%)
imits statistical reliability, espe-
ially of the logistic regression
odels (9), we chose to pool the
ata from both cohorts, analyze
hem as 1 group, and use the
resent cohort for validation of
utoff levels derived from previ-
us studies in patients with non–
T-segment elevation acute coro-
ary syndrome (6,7) to determine
he usefulness of GDF-15 for risk
tratification in the specific setting of
ardiac surgery.
ecruitment. In total, 2,026 patients were screened during
he study period. Five patients refused to participate in the
tudy, and in 76 patients surgery was cancelled. Complete
ata sets including GDF-15 levels were available from 1,458
atients (Fig. 1). One-year follow-up was 99.6% (n 1,452
atients).
etermination of GDF-15, NTproBNP, and hsTNT.
rterial blood samples for determination of GDF-15,
TproBNP, and hsTNT were obtained immediately before
nduction of anesthesia. Plasma was separated and stored at
80° C for further analysis. Analyses were performed by
lectrochemiluminescence immunoassays on Elecsys 2010
nalyzers (Roche Diagnostics, Mannheim, Germany).
GDF-15 was determined in plasma with a pre-
ommercial assay based on the electrochemiluminesence
mmunoassay principle on Elecsys (Roche Diagnostics,
annheim, Germany) (10). The assay has a sandwich
ormat with 2 monoclonal antibodies used for capture and
etection of serum or plasma GDF-15. The intra- and
nterassay coefficient of variation for GDF-15 levels be-
ween 0.1 and 16.0 ng/ml varied between 0.7% and 2.2%.
his new assay is highly correlated with a previously
escribed immunoradiometric assay for GDF-15 (11).
NTproBNP was determined as described recently (8,12)
tilizing an electrochemiluminescence immunoassay (Elec-
ys proBNP sandwich immunoassay; Roche Diagnostics) on
lecsys 2010. The lower detection limit of the assay was 5
g/ml. The interassay coefficient of variation was 9.3% at
30 pg/ml and 14.4% at 3,890 pg/ml.
hsTNT was determined by the electrochemiluminescence
ethod as described previously (electrochemiluminesence
mmunoassay; Elecsys 2010 analyzer, Roche Diagnostics)
13). The lower detection limit of this assay was 3 pg/ml.
he interassay coefficient of variation was 5.4% at 28 pg/ml
nd 7.1% at 2,350 pg/ml.
tandard risk factors and clinical outcomes. Pre-
perative left ventricular ejection fraction (LVEF) was
Abbreviations
and Acronyms
addES  additive
EuroSCORE
AUC  area under the
curve
GDF-15  growth
differentiation factor 15
hsTNT  high-sensitive
troponin T
LVEF  left ventricular
ejection fraction
NTproBNP  N-terminal
pro–B-type natriuretic
peptide
ROC  receiver-operating
characteristicraded as severely reduced (LVEF 30%), moderately
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u
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GDF-15 for Risk Stratification in Cardiac Surgery February 12, 2013:672–81reduced (LVEF 30 to 49%), or normal (LVEF50%). The
addES (14) was calculated from the prospectively sampled
cardiac surgery database and analyzed as a continuous
variable. The variables of the addES are presented in Online
Table 1. Estimated glomerular filtration rate was calculated
from pre-operative plasma creatinine by the abbreviated
Modifications of Diet in Renal Disease equation (15).
Clinical outcomes (30-day mortality, major complica-
tions, duration of treatment in the high-dependency unit)
were derived from the prospectively sampled cardiac surgery
database. All-cause 1-year mortality was determined from
the hospital database, by contacting the patient’s primary
physician and/or the patient or his or her next of kin.
Anesthesia, surgery, and cardiopulmonary bypass
management. Anesthesia and cardiopulmonary bypass
Figure 1 Consort Chart of Patient Recruitment
AV  aortic valve; CABG  coronary artery bypass grafting; MV  mitral valve; TVmanagement were performed as described recently (8).With the exception of patients undergoing off-pump coro-
nary artery bypass grafting (n  21) and transapical aortic
valve replacement (n  11) in 2009, surgery was performed
ith cardiopulmonary bypass in moderate hypothermia
sing antegrade blood cardioplegia. Forty-six patients un-
erwent deep hypothermic circulatory arrest with or without
elective perfusion. A description of the surgical procedures
s given in Figure 1.
tatistical analyses. Data were analyzed by MedCalc
2.3.0 statistical software package (MedCalc Software,
ariakerke, Belgium) and R version 2.14.2 (R Develop-
ent Core Team, Vienna, Austria).
Data are presented as mean  SD if normally distributed
or otherwise as median and 25%/75% quartiles or 95%
confidence interval (CI) of the median. Statistical signifi-
spid valve. tricucance was assessed at the 5% level (p  0.05 is statistically
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February 12, 2013:672–81 GDF-15 for Risk Stratification in Cardiac Surgerysignificant). Correlation analyses were performed by Spear-
man’s rank correlation test.
To allow better comparisons with the addES, mortality
was primarily calculated as 30-day mortality. One-year
mortality was used for construction of Kaplan-Meier
survival curves and Cox proportional hazards regression
analyses.
Post-operative morbidity was defined as a combined
endpoint of: 1) more than 1 point in the Major Adverse
Events and Complications Score according to Schön et
al. (16) (need of renal replacement therapy, reintubation,
stroke (Rankin disability score 1 [17]), low cardiac output
syndrome); and/or 2) need for high-dependency unit (in-
tensive care unit plus intermediate care) treatment of 10
days.
Comparisons between groups for univariate predictors of
outcome were performed by a 2-sided chi-square test for
categorical variables and Mann-Whitney test or Kruskal-
Wallis test for continuous variables, where appropriate.
Area under the curve (AUC) as well as cutoff values for
mortality and morbidity (i.e., the values with the maximal
sum of sensitivity and specificity) were derived from
receiver-operating characteristic (ROC) curve analyses
(C-statistics). Differences between AUCs were calculated
according to DeLong and coworkers (18).
To determine the predictive capacity of GDF-15,
NTproBNP, and hsTNT in addition to the addES and
duration of surgery as a measure of the severity of the
surgical insult, multiple logistic regression and Cox propor-
tional hazards models were employed. The addES was
forced in all models and backward elimination of the
variables GDF-15, NTproBNP, hsTNT, and duration of
surgery was employed for final model selection. Survival
analysis with the Cox proportional hazards methods were
used to identify which factors have a significant influence on
30-day and 1-year survival. In all models addES and
duration of surgery were entered as continuous variables.
GDF-15, NTproBNP, and hsTNT were analyzed sepa-
rately both as continuous as well as dichotomized variables
(cutoffs: GDF-15 1.8 or 1.8 ng/ml, NTproBNP
2,000 pg/ml or 2000 pg/ml, hsTNT14 pg/ml or 14
pg/ml) according to established cutoff values (19,20). Ad-
ditionally, analyses according to surgical priority (elective vs.
urgent or emergency cases) were performed.
Net reclassification improvement and integrated discrimina-
tion improvement were calculated as described recently (21).
Results
Demographics, surgical course, and general outcomes. De-
mographics, cardiovascular risk factors, risk scores including
different versions of EuroSCORE, estimated glomerular
filtration rate, and pre-operative plasma levels of GDF-15,
NTproBNP, and hsTNT are presented in Table 1. Thirty-day
mortality, 1-year mortality, and post-operative morbidity
(defined as more than 2 major complications and/or ahigh-dependency unit stay of 10 days) were 3.4%, 7.6%,
and 14.4%, respectively. Univariate analyses of patients with
post-operative mortality and morbidity revealed that pa-
tients with an adverse outcome had a higher addES and a
more pronounced cardiovascular risk profile (Table 1).
Factors influencing GDF-15. GDF-15 was correlated
with various demographic and physiological variables rep-
resentative of cardiovascular risk including NTproBNP and
hsTNT concentrations (see Online Table 2). Analysis of
GDF-15 in different addES mortality risk categories re-
vealed significantly different and increasing GDF-15 levels
in each EuroSCORE category (Fig. 2).
ROC curve analyses. ROC curve analysis of GDF-15 and
30-day mortality in the total cohort revealed an AUC of
0.83 (95% CI: 0.81 to 0.85; p  0.0001) and a cutoff value
of 1.63 ng/ml (sensitivity 76.5%, specificity 78.0%). The
respective results for the combined morbidity endpoint
(Major Adverse Events and Complications Score2 and/or
high-dependency unit time 10 days) revealed an AUC of
0.8 (95% CI: 0.78 to 0.82; p  0.0001) in the total cohort.
The cutoff value was GDF-15 1.66 ng/ml with a sensi-
tivity of 62.9% and a specificity of 83.6%.
An analysis restricted to elective patients revealed a cutoff
level of 1.76 ng/ml for 30-day mortality (AUC: 0.78; 95%
CI: 0.76 to 0.81; sensitivity 72.0, specificity 83.6; p 
0.0001).
The ROC curve analysis for 30-day mortality and dura-
tion of surgery and the respective cutoff value was an AUC
of 0.71 (95% CI: 0.69 to 0.74; p  0.0001; cutoff value
284 min).
ROC curve analyses revealed no significant differences
between the AUC of the addES and GDF-15 levels for
30-day mortality (AUC: 0.81; 95% CI: 0.79 to 0.83; p 
0.515) and for the combined morbidity endpoint (AUC:
0.78; 95% CI: 0.75 to 0.80; p  0.256).
The AUCs of combined multiple regression models of
the addES and GDF-15, hsTNT, and NTproBNP are
given in Table 2. The AUC of the combined model with
addES and GDF-15 was significantly higher than of the
addES alone. The combined model of addES and hsTNT
was superior to the addES alone but had a significantly
lower AUC than the combined addES and GDF-15 model.
It is of note that multiple regression failed to identify
NTproBNP as an independent risk factors/predictor of
30-day mortality.
GDF-15,NTproBNP, hsTNT in survivors and nonsurvivors.
Comparative analysis of GDF-15 levels in survivors and
nonsurvivors showed significantly higher GDF-15 levels in
30-day nonsurvivors (Table 1). Employing a cutoff level of
1.8 ng/ml revealed a markedly increased 1-year mortality
rate in the total cohort, after stratification for different
EuroSCORE risk categories, and cutoff levels of 2000
pg/ml for NTproBNP and 14 pg/ml for hsTNT (Table 3).
Employing the respective cutoff level for NTproBNP in
the different addES risk categories revealed a significant
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GDF-15 for Risk Stratification in Cardiac Surgery February 12, 2013:672–81Patient Characteristics, Surgical Course, Mortality, and Morbidity in 1,458 Patients Undergoing Cardiac SurgeryTable 1 Patient Characteristics, Surgical Course, Mortality, and Morbidity in 1,458 Patients Undergoing Cardiac Surgery
Total Cohort
30-Day Mortality Combined Morbidity Endpoint
Alive Deceased Significance Not Fulfilled Fulfilled Significance
Number of cases 1,458 1,408 (97%) 50 (3%) 1,246 (86%) 210 (14%)
Demographic data
Female 443 (30%) 420 (30%) 23 (45%) p 0.054 372 (30%) 71 (34%) p 0.284
Male 1,015 (70%) 986 (70%) 28 (55%) 874 (70%) 139 (66%)
Age, yrs 68 (59–74) 68 (59–74) 74 (69–79) p < 0.001 68 (58–73) 72 (67–78) p < 0.001
BMI, kg/m2 27 (25–30) 27 (25–30) 26 (23–28) p 0.046 27 (25–30) 26 (24–30) p  0.003
History
Hyperlipidemia 904 (62%) 873 (62%) 30 (59%) p 0.704 766 (61%) 136 (65%) p 0.414
Arterial hypertension 1,229 (84%) 1,184 (84%) 44 (86%) p 0.85 1,039 (83%) 188 (90%) p  0.035
Diabetes mellitus 419 (29%) 396 (28%) 22 (43%) p  0.02 338 (27%) 81 (39%) p  0.001
Carotid stenosis 48 (3%) 46 (3%) 2 (4%) p 0.952 33 (3%) 15 (7%) p  0.002
Peripheral artery
disease
182 (12%) 173 (12%) 9 (18%) p 0.49 144 (12%) 38 (18%) p  0.011
Stroke* 84 (6%) 77 (5%) 6 (12%) p < 0.001 64 (5%) 20 (10%) p  0.018
Risk stratification
NYHA functional class
III/IV
629 (43%) 593 (42%) 35 (69%) p < 0.001 503 (40%) 125 (60%) p < 0.001
NYHA functional class
I/II
828 (57%) 812 (58%) 16 (31%) 743 (60%) 84 (40%)
LVEF 30% 67 (5%) 55 (4%) 12 (24%) p < 0.001 42 (3%) 25 (12%) p < 0.001
LVEF 50% 359 (25%) 337 (24%) 21 (41%) p  0.003 283 (23%) 76 (36%) p < 0.001
ASA 3 (3–3) 3 (3–3) 3 (3–4) p < 0.001 3 (3–3) 3 (3–4) p < 0.001
Additive EuroSCORE 5 (3–8) 6 (3–8) 10 (7–12) p < 0.001 5 (3–7) 8 (7–11) p < 0.001
Logistic EuroSCORE 0.05 (0.02–0.09) 0.05 (0.02–0.09) 0.20 (0.08–0.32) p < 0.001 0.04 (0.02–0.08) 0.11 (0.03–0.06) p < 0.001
Logistic EuroSCORE II† 0.02 (0.01–0.04) 0.02 (0.01–0.04) 0.08 (0.03–0.18) p < 0.001 0.01 (0.01–0.03) 0.06 (0.02–0.13) p < 0.001
Angina pectoris 796 (55%) 772 (55%) 23 (45%) p 0.252 679 (54%) 116 (55%) p 0.910
Previous MI 378 (38%) 356 (25%) 21 (41%) p  0.010 303 (24%) 74 (35%) p  0.001
Previous cardiac surgery 131 (9%) 124 (9%) 7 (14%) p 0.461 99 (8%) 32 (15%) p  0.001
Active endocarditis 31 (2%) 28 (2%) 3 (6%) p 0.165 20 (2%) 11 (5%) p  0.002
Circulatory support‡ 46 (3%) 35 (2%) 11 (22%) p < 0.001 23 (2%) 23 (11%) p < 0.001
Type of surgery
CABG 982 (67%) 944 (67%) 38 (75%) p 0.427 827 (66%) 156 (74%) p  0.029
No CABG 476 (33%) 462 (33%) 13 (25%) 419 (34%) 54(26%)
Surgical priority
Elective 1,211 (83%) 1186 (84%) 25 (49%) p < 0.001 1,077 (86%) 132 (63%) p < 0.001
Urgent and emergency 247 (17%) 220 (16%) 26 (51%) 169 (14%) 78 (37%)
Laboratory analyses
NTproBNP (n 1,446),
pg/ml
503 (160–1413) 488 (155–1302) 2,215 (836–5079) p < 0.001 438 (141–1058) 1,758 (486–4,617) p < 0.001
hsTNT (n 1,445),
ng/ml
13 (6–31) 13 (6–29) 77 (26–566) p < 0.001 12 (6–25) 34 (15–144) p < 0.001
GDF-15 (n 1,458),
ng/ml
1.057 (765–1592) 1.038 (756–1519) 2.537 (1640–5055) p < 0.001 0.980 (727–1381) 2.003 (1,271–3,218) p < 0.001
eGFR (n 1,456),§
ml/min/1.73 m2
80 (63–98) 80 (63–98) 71 (46–86) p  0.009 82 (66–100) 64 (46–85) p < 0.001
Intraoperative course
Duration surgery, min 252 (211–302) 250 (210–300) 316 (259–415) p < 0.001 245 (206–292) 295 (245–378) p < 0.001
Duration CPB, min 110 (87–144) 109 (87–142) 170 (117–228) p < 0.001 107 (86–137) 142 (108–190) p < 0.001
Aortic crossclamp time,
min
86 (67–113) 86 (67–113) 106 (85–147) p  0.008 84 (66–110) 108 (82–140) p < 0.001
Values are median (interquartile range [25–75 percentile]) for continuous variables and n (%) for categorical variables. The combined morbidity endpoint was defined as 2 complications (need of new
renal replacement therapy, reintubation, stroke [Rankin grade 1], low cardiac output syndrome) and/or need for a high-dependency unit treatment of 10 days. *History of stroke is defined as former
ischemic cerebral infarction or hemorrhagic stroke with a Rankin grade 1. †The logistic EuroSCORE II was calculated retrospectively with the assumption that no patient showed severe impairment of
mobility secondary to musculoskeletal or neurological dysfunction and with the endpoint 30-day mortality. ‡Circulatory support with intravenous inotropes, vasopressors, and/or intra-aortic
counterpulsation. §Estimated glomerular filtration rate (eGFR) calculated by the Modifications of Diet in Renal Disease equation.ASA American Society of Anesthesiology grading; BMI  body mass index; CABG  coronary artery bypass grafting; CPB  cardiopulmonary bypass; GDF-15  growth-differentiation factor 15;
sTNT  high-sensitive troponin T; LVEF  left ventricular ejection fraction; MI myocardial infarction; NTproBNP  N-terminal pro–B-type natriuretic peptide; NYHA  New York Heart Association.
T
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(30-day mortality of 8.2% in 294 patients with NTproBNP
2,000 pg/ml vs. 16.1% in 124 patients with a NTproBNP
2000 pg/ml; difference: 7.9%; 95% CI: 0.91 to 16.2%; p
0.0244). Comparably, stratification according to the respec-
tive hsTNT cutoff showed a significant difference only in
patients with an addES from 6 to 10 (30-day mortality of
4.6% in 172 patients with hsTNT 14 pg/ml vs. 14.6% in
246 patients with a hsTNT 14 pg/ml; difference: 10%;
95% CI: 4.0 to 15.7%; p  0.0019).
Logistic regression analysis. Logistic regression analysis
for 30-day and 1-year mortality (Table 4) including addES,
GDF-15, NTproBNP, hsTNT, and duration of surgery
Figure 2
Pre-Operative Plasma Concentrations
of GDF-15 in Patients Undergoing Cardiac
Surgery With Different Additive EuroSCORE
Risk Categories (0 to 2, 3 to 5, 6 to 10, >10)
Data are given as box plots showing median and 5%, 25%, 75%, and 95% per-
centiles. All groups are significantly different from each other (Kruskal-Wallis
test: p  0.0001). GDF-15  growth differentiation factor 15.
Correlation Coefficients and Receiver-Operatingharac eristic Curv Analyses of Different MultiReg ess Models for 30-Day Mortality in Card
Table 2
C rrelation Coefficients and Receiv
Characteristic Curve Analyses of Di
Regression Models for 30-Day Mort
Model
Multiple Correlation
Coefficient
addES 0.2296
(n  1,458) p 0.001 (0.
addES  hsTNT 0.2827
(n  1,445) p 0.001 (0.
addES  NTproBNP* 0.2265
(n  1,446) p 0.001 (0.
addES  GDF-15 0.2736
(n  1,458) p 0.001 (0.
Comparative analyses of the additive EuroSCORE (addES) and continu
markers for risk stratification. *N-terminal pro–B-type natriuretic peptide (NT
AUC  area under the curve; N/A  not applicable; other abbreviations asrevealed that only the addES and pre-operative GDF-15
were consistent independent predictors of mortality in the
total cohort and in elective patients.
Cox proportional hazard regression. Cox proportional
hazards regression including addES, GDF-15, NTproBNP,
hsTNT, and duration of surgery as continuous variables
revealed that pre-operative GDF-15 levels are significant
factors influencing 1-year mortality. NTproBNP either in
elective as well as in urgent or emergency cases was not
entered in these models. For elective patients only the
addES and GDF-15 were predictors of mortality (Online
able 3).
aplan-Meier survival analyses. The effects of high pre-
operative GDF-15 levels (cutoff level 1.8 ng/ml or 1.8
ng/ml) on post-operative mortality analyzed by Kaplan-
Meier statistics are displayed in Figure 3. In patients with
high NTproBNP (2,000 pg/ml) or high hsTNT levels
(14 pg/ml), the presence of high GDF-15 levels (1.8
ng/ml) were associated with significantly worse survival rate.
Net reclassification improvement and integrated discrim-
ination improvement analyses. The addition of GDF-15
(categorized in 2 groups according to a cutoff level of 1.8
ng/ml) resulted in a 41.4% net reclassification improvement
(95% CI: 19.2 to 63.7%; p  0.0001); for the model
predicted mortality risk categories: 0 to 2%, 2 to 5%, 5 to
10%, and10%) and an integrated discrimination improve-
ment of 0.038 (95% CI: 0.022 to 0.0547; p0.0001)
compared to a model only including the addES (Table 5;
Online Table 4).
Discussion
In line with recent observations in patients with heart failure
and coronary artery disease (1–7,11) the findings of the
present study show that pre-operative plasma GDF-15
levels are closely related to relevant measures of cardiopul-
monary function, post-operative morbidity, and short- and
long-term mortality in patients undergoing cardiac surgery.
In addition to clinical judgment, pre-operative risk as-
sessment in cardiac surgery is typically performed by risk
urgery Patientserating
nt Multiple
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AUC Difference
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AUC Difference Versus
addES  GDF-15
N/A 0.0443
.824) p 0.0097
0.0146 0.0296
.838) p 0.1007 p 0.0489
0.0000 0.0443
.824) p 1.0 p 0.0097
0.0443 N/A
.824) p 0.0097
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ffere
ality
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cardiac surgery is the EuroSCORE. It is available in a classical
additive (14) and 2 logistic versions, with the latest version, the
logistic EuroSCORE II, published very recently (22).
In contrast to the setting of cardiac surgery, risk stratifi-
cation in medical patients with heart failure and coronary
artery disease is typically accomplished by determination of
humoral markers that are reflective of the severity of
cardiopulmonary dysfunction (i.e., natriuretic peptides [19)
and myocardial integrity (troponins [13,20]). Interestingly,
these variables may also be used for risk stratification in
cardiac surgery patients; sometimes adding additional infor-
mation if performed “on top” (e.g., in addition to a
conventional risk scores such as the EuroSCORE [23]).
The cytokine GDF-15 differs from the humoral markers
presently used for risk stratification in cardiac patients in so
far that it is not only increased by cardiac dysfunction (i.e.,
volume overload and cardiac distension) but also by “circu-
latory stress” (1,2). Thus, the plasma levels of this peptide
may be not only representative of cardiac dysfunction but
also reflective of the circulatory disturbances associated with
One-Year Mortality in Patients Undergoing Cardiac Surgery StratifieAccording t Pre-Operativ Plasma Levels of GDF-15 and Other RisTable 3 One-Year Mortality i Patie ts Un ergoing Cardiac SurAccording to Pre-Operative Plasma Levels of GDF-15 a
GDF-15 <1.8 ng/ml
Total Survivors Nonsurvivors
1-Year
Mortality T
NTproBNP <2000 pg/ml 1028 996 32 3.1% 1
NTproBNP >2000 pg/ml 132 120 12 9.1% 1
hsTNT <14 pg/ml 702 684 18 2.6% 4
hsTNT >14 pg/ml 52 46 6 5.7% 2
addES 0–2 260 256 4 1.5%
addES 3–5 404 395 9 2.2%
addES 6–10 446 425 21 4.7% 1
addES >10 58 48 10 17.2%
Patients undergoing cardiac surgery stratified to an established GDF-15 cutoff level for 30-day mor
by other risk stratification methods according to cutoff levels derived from previous studies. *Diff
AUC  area under the curve; N/A  not applicable; other abbreviations as in Table 1.
Logistic Regression for 30-Day and 1-Year MortalityTable 4 Logistic Regression for 30-Day and 1-Year Mortality
30-Day Mortality
Covariate All Patients (n  1,444) Elective Patien
Additive EuroSCORE 1.2650 (1.158 to 1.381) 1.3106 (1.151
p 0.0001 p 0.
GDF, ng/ml 1.0623 (1.002 to 1.126) 1.2342 (1.113
p 0.0423 p 0.
NTproBNP, pg/ml Not included Not inc
hsTNT, pg/ml 1.0003 (1.000 to 1.0058)
p 0.0474
Not inc
Duration of surgery, min 1.0033 (1.0009 to 1.0058) Not inc
p 0.0083
Chi-square 81.783 35.3
p 0.0001 p 0.
AUC 0.829 (0.809 to 0.848) 0.801 (0.77
Values are odds ratio (95% confidence interval). Results of backward logistic regression employ
different models for 30-day and 1 year mortality.
Abbreviations as in Tables 1 and 2.severe cardiovascular disease and/or heart failure (i.e., in-
flammation and systemic hypoperfusion). In line with these
assumptions it has been shown that GDF-15 had a high
predictive capacity for a combined morbidity and mortality
endpoint in patients with heart failure (5) and that patients
presenting with acute myocardial infarction and with high
plasma GDF-15 levels benefited more from an aggressive
interventional approach than patients with low levels of this
cytokine (6).
The findings of the present study extend the prognostic
relevance of increased plasma levels GDF-15 also to pa-
tients undergoing cardiac surgery. The 30-day mortality
cutoff level derived from the present study for elective
patients (1.78 ng/ml) is highly comparable to the 1-year
mortality cutoff derived from medical patients with an acute
coronary syndrome (1.8 ng/ml) (6,7); a finding supporting
the use of this “medical” cutoff also in the present compar-
ative analyses in “surgical” patients.
GDF-15 significantly improved the predictive capacity of
the addES for predicting 30-day mortality. Interestingly,
the discriminatory capability of GDF-15 remained signifi-
atification MethodsS ratified
her Risk Stratification Methods
GDF-15 >1.8 ng/ml
Survivors Nonsurvivors
1-Year
Mortality Difference* Significance
146 26 17.8% 14.7% (8.7 to 21.9%) p 0.0001
94 40 29.9% 20.7 (10.9 to 30.3) p 0.0001
432 26 11.5% 8.9 (1.6 to 20.1) p 0.0017
167 60 26.4% 20.7 (14.6 to 27.3%) p 0.0001
13 2 13.3% 11.8 (–0.1 to 38.9%) p 0.0338
50 5 9.1% 6.9 (0.48 to 17.8%) p 0.0182
117 30 20.4% 15.7 (9.0 to 23.3%) p 0.0001
37 30 44.8% 27.6 (10.4 to 42.9) p 0.0019
patients with cardiovascular disease (6,7) and further analyzed according risk categories derived
in 1-year mortality between patients with GDF-15 levels  or  1.8 ng/ml.
1-Year Mortality
1,201) All Patients (n  1,438) Elective Patients (n  1,196)
.4913) 1.2532 (1.1761 to 1.3355) 1.2887 (1.1891 to 1.3597)
p 0.0001 p 0.0001
.3675) 1.1389 (1.0635 to 1.2198) 1.2315 (1.1153 to 1.3597)
p 0.0002 p 0.0001
Not included Not included
Not included Not included
1.0022 (1.0003 to 1.0041) Not included
p 0.0261
127,026 73.514
p 0.0001 p 0.0001
823) 0.797 (0.775 to 0.817) 0.770 (0.745 to 0.794)
itive EuroSCORE, GDF-15, NTproBNP, hsTNT, and duration of surgery as continuous variables indk Strgery
nd Ot
otal
64
34
58
27
15
55
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February 12, 2013:672–81 GDF-15 for Risk Stratification in Cardiac SurgeryFigure 3 Kaplan-Meier Survival Probability Curves
Growth differentiation factor 15 (GDF-15) cutoff level (A) 1.8 ng/ml or 1.8 ng/ml (6,7), (B) according to established cutoff levels (18) for N-terminal pro–B-type natri-
uretic peptide (NTproBNP), and (C) high-sensitive troponin T (hsTNT) (19). Log-rank analyses with Bonferroni correction for multiple testing. The number of patients at
risk at every point in the Kaplan-Meier plot can be evaluated as the number of patients at risk at t  0 minus the number of events.
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factors. As highlighted in Table 3 and Figure 3, patients
with GDF-15 levels higher than 1.8 ng/ml always had a
much higher mortality than those with GDF-15 levels
below this cutoff, not only in the different EuroSCORE risk
categories, but also after stratification for high plasma
concentrations of NTproBNP or hsTNT. This finding has
important clinical implications, as NTproBNP and hsTNT
added only limited prognostic information on the mortality
risk: NTproBNP and hsTNT were only helpful to stratify
patients with an addES between 6 and 10. In contrast to
other studies showing that NTproBNP adds prognostic
capabilities in addition to the EuroSCORE in cardiac
surgical patients (23), this hormone was no independent risk
factor/predictor for mortality in this study: neither in a
combined multiple regression model of the additive Euro-
SCORE and NTproBNP nor in the logistic regression and
the Cox regression analyses for 30-day and 1-year mortality.
One explanation for this observation may be the fact that
the sample size of the present study is much larger than in
previous studies analyzing the prognostic capabilities of
NTproBNP. This, however, is speculative.
Comparably, as highlighted by the Cox regression anal-
ysis, hsTNT and duration of surgery were only predictors of
mortality in the total cohort, including patients scheduled
for surgery as urgent or emergency cases, but not in elective
patients. Taken together these findings clearly show that the
determination of GDF-15 adds important prognostic infor-
mation in addition to conventional risk stratification tools.
Study limitations. First, despite very recently a new ver-
sion of the EuroSCORE, the logistic EuroSCORE II, has
been presented, we used the addES as a comparator for
“conventional” risk stratification as primarily planned and
described in the study protocol. We recognize that the
logistic EuroSCORE II has been suggested to have a better
discriminatory power than the older versions. However, this
Net Reclassification Improvement of AdditiveEuroSCORE With GDF-15 for 30-Day MortalityTable 5 Ne Reclassificatio Improvement ofEuroSCORE With GDF-15 for 30-Day
Initial Model
(Risk Categories)
Updated M
0–2% 2–5%
Outcome absent
0%–2% 656 42
2%–5% 348 0
5%–10% 0 120
10%–100% 0 10
Outcome present
0%–2% 4 1
2%–5% 3 0
5%–10% 0 5
10%–100% 0 1
Net reclassification improvement for 30-day mortality between the ad
additive EuroSCORE with GDF-15 employing a cutoff level 1.8 ng/m
improvement of 0.4136 (95% confidence interval: 0.1914–0.6358; p
confidence interval: 0.0219–0.0546; p  0.0001).
Abbreviations as in Tables 1 and 2.score has been developed to estimate hospital mortality atthe base hospital and thus is difficult to be applied in an
institution such as ours in which a relevant number of
patients is transferred rather early after surgery to other
departments or other hospitals.
Second, to avoid overfitting of the logistic regression and
the Cox proportional hazards regression analyses, not all
variables with significant differences in the univariate anal-
yses were integrated in the model. Thus, it cannot be
completely ruled out that a relevant physiological variable
influencing the plasma concentration of GDF-15 might
have been missed in this analysis.
Third, besides taking into account surgical priority, no
further meaningful subgroup analyses of specific patient
groups and indications could be performed due to the low
number of events. It is rather plausible that the relationship
among GDF-15, hsTNT, and NTproBNP in specific
subsets of patients and indications (i.e., emergency revascu-
larization for myocardial infarction vs. elective aortic valve
replacement) may differ from the “mixed” relationship
observed in the total cohort of patients. This is an important
limitation and needs to be specifically addressed in future
studies.
Conclusions
The present analysis of a large population shows that the
pre-operative plasma level of GDF-15 is an independent
predictor of post-operative mortality and morbidity in
cardiac surgery patients, can further stratify beyond estab-
lished risk scores such as the EuroSCORE and other
cardiovascular risk markers such as NTproBNP or hsTNT,
and thus adds important additional information for risk
stratification in these patients.
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